The pediatric neurologist at Nationwide Children's Hospital discussed the epilepsy research studies that he is excited about in 2023. [WATCH TIME: 4 minutes]
WATCH TIME: 4 minutes
“For us at Nationwide Children's Hospital, to be able to participate in those studies would be amazing because the treatments right now work, but they're not great. Opportunities to really make the disease minimized by targeting that gene would be fun that we hope to participate in.”
Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS), both severe, genetic forms of epilepsy, typically begin in the first year of life or early childhood. Through the advance in technology with electronic patient records, clinicians have easier access to large sets of data. After applying algorithms, they can help identify specific patients for research studies such as those with DS and LGS. Besides easier recruitment with advanced technologies such as algorithms, genetic therapies are another advancement that has gained traction as potential treatment with these types of epilepsies.
Recently, Anup Patel, MD, pediatric neurologist at Nationwide Children's Hospital, sat down with NeurologyLive® in an interview to discuss the potential of research studies in 2023 regarding different types of epilepsy disorders through advanced technology tools. Patel, professor of clinical pediatrics and neurology at Nationwide Children's Hospital and at The Ohio State University College of Medicine, also talked about the studies that his institute hopes to participate in with the focus on developing better targeted therapies for patients with epilepsy.